2 citations
,
May 2011 in “Hair transplant forum international” The Intruder is a tool used for safely preparing the area where a donor's tissue is taken.
January 2025 in “Skin Health and Disease” Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.
48 citations
,
November 2017 in “Journal of the American Academy of Dermatology” Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
March 2019 in “Sexual medicine reviews”
March 2014 in “Journal of The American Academy of Dermatology”
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in teens with severe alopecia areata.
November 2023 in “Journal of the American Academy of Dermatology” August 2023 in “Journal of The American Academy of Dermatology” July 2023 in “JAAD Case Reports” January 2023 in “Journal of the American Academy of Dermatology” October 2020 in “Journal of the American Academy of Dermatology” June 2020 in “Journal of the American Academy of Dermatology” August 2018 in “Journal of Investigative Dermatology”
February 2014 in “Journal of The American Academy of Dermatology”
February 2012 in “Journal of The American Academy of Dermatology”
37 citations
,
October 2017 in “Clinical and Experimental Dermatology” Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
258 citations
,
July 2005 in “Journal of lipid research” DGAT1 enzyme helps make diacylglycerols, waxes, and retinyl esters.
9 citations
,
October 2019 in “Dermatologic Therapy” Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.
44 citations
,
October 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in Korean patients.
1 citations
,
December 2024 in “Dermatology and Therapy” The STRIAA tool helps doctors quickly and effectively assess the severity of Alopecia Areata.
65 citations
,
February 2011 in “Molecular cancer therapeutics” CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.
July 2024 in “Journal of Investigative Dermatology”
January 2023 in “National Journal of Physiology, Pharmacy and Pharmacology” Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.
10 citations
,
August 2020 in “Acta histochemica” All-trans-retinoic acid stops mink hair growth by affecting cell growth and causing cell death.
February 2007 in “Technology in Society” July 2024 in “Journal of Investigative Dermatology” ATR04-484 ointment shows promise for treating skin issues from cancer therapies.
4 citations
,
January 2022 in “Dermatologic Therapy” Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.
7 citations
,
August 2024 in “Clinical and Experimental Dermatology” Upadacitinib is effective and safe for treating severe alopecia areata in teens.